Product Description
Arzoxifene is a synthetic, aromatic derivative with anti-estrogenic properties. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Arzoxifene)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Endometrial Cancer|Ovarian Cancer|Breast Cancer
Phase 3: Osteoporosis, Postmenopausal|Osteoporosis|Breast Cancer
Phase 2: Osteoporosis|Endometrial Cancer|Breast Cancer|Peritoneal Cancer|Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GJAD | P3 |
Completed |
Osteoporosis |
2009-11-30 |
|
| H4Z-MC-GJAV | P2 |
Completed |
Osteoporosis |
2009-10-01 |
|
| H4Z-MC-GJAD | P3 |
Completed |
Osteoporosis, Postmenopausal |
2009-06-01 |
|
| H4Z-MC-GJAR | P3 |
Completed |
Osteoporosis, Postmenopausal |
2008-07-01 |
|
| GJAR | P3 |
Completed |
Osteoporosis |
2008-07-01 |
|
| KUMC-HSC-7264-97 | P2 |
Completed |
Breast Cancer |
2008-07-01 |
|
| CASE-CCF-4713 | P2 |
Completed |
Breast Cancer|Ovarian Cancer |
2005-04-01 |
|
| CDR0000066453 | P2 |
Completed |
Breast Cancer |
2001-06-01 |
|
| LILLY-H4Z-MC-JWWI | P2 |
Completed |
Endometrial Cancer |
None |
|
| LILLY-H4Z-MC-JWWJ | P2 |
Completed |
Peritoneal Cancer|Ovarian Cancer |
None |
|
| H4Z-MC-GJAE | P3 |
Completed |
Osteoporosis, Postmenopausal |
None |
|
| H4Z-MC-JWXD | P3 |
Completed |
Breast Cancer |
None |
|
| H4Z-MC-JWXM | P4 |
Completed |
Endometrial Cancer|Ovarian Cancer|Breast Cancer |
None |